Nuclera Appointed Carl Raimond as New CEO
The Cambridge-based protein synthesis firm selected the former Thermo Fisher leader to oversee commercial growth.
Updated on Sept. 22, 2026 in People
Live Poll
Do you generally trust that new executive leadership will improve a company's long-term product delivery?
Nuclera has officially appointed Carl Raimond as its new Chief Executive Officer. As part of the leadership transition, co-founder Dr. Michael Chen has moved into the role of Chief Scientific and Business Officer.
Why it matters
The leadership change marks the next phase in the company's evolution as the board looks to prioritize customer adoption and commercial execution for its protein production technologies.
The company leverages 10 years of internal expertise in protein synthesis. This follows Thermo Fisher Scientific's $3.1 billion acquisition of Olink Proteomics in 2023.
The players
Carl Raimond
He is the new CEO of Nuclera and previously served as the President of Proteomic Sciences at Thermo Fisher Scientific.
Dr. Michael Chen
He is a co-founder of Nuclera who has transitioned to the role of Chief Scientific and Business Officer.
Nuclera
This Cambridge-based company develops digital microfluidic technologies for protein production and antibody screening.
Thermo Fisher Scientific
This global life sciences supplier is a major industry player that previously acquired Olink Proteomics.
The details
Nuclera specializes in cell-free protein synthesis and digital microfluidics to advance antibody screening workflows at customer sites. The company expanded its reach significantly in May 2026 with the launch of new antibody service capabilities.
Timeline
2023: Thermo Fisher Scientific acquired Olink Proteomics.
May 2026: Nuclera launched its antibody service capabilities.
September 2026: Nuclera appointed Carl Raimond as CEO.
Market Landscape
The hire of a former Thermo Fisher executive signals Nuclera's intent to compete in the broader proteomics sector following major industry consolidations like the 2023 Olink Proteomics acquisition. This strategic move positions the company to scale its commercial operations against more established global life sciences competitors.
Customers currently utilizing the company's antibody screening workflows may see an increased emphasis on on-site service support. Clients should monitor future updates regarding expanded service capabilities as the firm shifts toward a focus on wider commercial adoption.
The takeaway
The appointment of an executive with a background in major acquisitions suggests a move toward aggressive commercial scaling. Clients and partners should expect a renewed focus on integrating these protein synthesis tools directly into existing laboratory workflows.
Further reading
For more on local leadership changes, visit the People section.
Live Poll
Do you generally trust that new executive leadership will improve a company's long-term product delivery?
